Trump signed an executive order on access to treatment using psychedelic drugs
19 April 06:08
U.S. President Donald Trump has signed an executive order aimed at accelerating access to medical research and treatment using psychedelic drugs.
This was reported by Reuters, according to "Komersant Ukrainian".
The U.S. Food and Drug Administration (FDA) is, in particular, to consider the potential use of ibogaine, which, according to veterans’ organizations, may help in the treatment of post-traumatic stress disorder.
During an event in the Oval Office, federal officials stated that the reforms could pave the way for the recognition of the medical use of such drugs following successful clinical trials.
Trump also announced $50 million in funding for federal research on ibogaine.
During the signing ceremony, he stated that he had only recently learned about ibogaine.
“I’ve heard a little bit about it over the last year… I hadn’t heard anything about it before. It was almost taboo. It’s no longer taboo,” he said.
Ibogaine—a substance derived from an African shrub—is classified in the U.S. as a drug with a high risk of abuse. At the same time, treatment centers using this substance operate in some countries, notably Mexico.
